Company overview
Basic information
Company name
Vilnius Corporate Finance, MB
Company code
306153130
Registered address
Vilnius, Konstitucijos pr. 7, LT-09308
Registration date
2022-09-28
Company age: 4 y. 1 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
None
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Business and other management consultancy activities
Sector
Užsienio subjektų kontroliuojamos ne finansų bendrovės
Ownership form
Private foreign capital
MB "Vilnius Corporate Finance"
Company code: 306153130
Address: Vilnius, Konstitucijos pr. 7, LT-09308
Description
This description was generated by artificial intelligence.
Vilnius Corporate Finance, MB (company code 306153130) is an operational private small partnership registered on 28 September 2022. The company is classified as a private enterprise under private ownership, with foreign natural and legal persons holding more than 50% of the entity’s authorised capital. Its governance structure is listed as CEO only, and it is identified as a micro company. The business operates in the sector of non-financial companies controlled by foreign entities and carries out N.70.20.00 Business and other management consultancy activities. The registered address is Konstitucijos pr. 7, Vilnius, LT-09308, in Vilnius city municipality, Vilnius County. Financially, the company increased its revenue from €48.5K in 2023 to €297.5K in 2024. Net profit rose from €6.9K to €182.3K over the same period, with the net profit margin improving from 14.2% to 61.3%. Total assets stood at €196.0K in 2024, while equity was €185.9K and liabilities €10.1K. The available dataset also indicates staff metrics for so far in 2026, although no employee or wage figures are provided.
Download a detailed company report
Make confident decisions with all the information about Vilnius Corporate Finance, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.